Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Will Lead Osteoarthritis Treatment with Zilosul's FDA Success

AM

Invested

Community Contributor

Published

03 Oct 25

AmirV's Fair Value

AU$5.50

93.1% undervalued

07 Oct

AU$0.38

1Y

81.0%

7D

5.6%

Loading

1Y

81.0%

7D

5.6%

You can edit this narrative until Oct 4 12:50 AM. Then, changes will post as Updates.

Author's Valuation

AU$5.593.1% undervalued

AmirV's Fair Value

AmirV'sFair Value

AU$5.5

93.1% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

120.05%

Biotech revenue growth rate

8.67%